Infertility

INVO Bioscience Enters Exclusive U.S. Licensing Agreement with Ferring Pharmaceuticals to Commercialize the Novel INVOcell™ System for Use in the Treatment of Infertility

Retrieved on: 
Tuesday, November 13, 2018
Fertility medicine, Medicine, Biology, Human reproduction, Infertility, Fertility, Assisted reproductive technology

INVO Bioscience also retains certain limited rights to establish INVO clinics that exclusively commercialize INVO cycles and will retain commercialization rights outside the U.S.

Key Points: 
  • INVO Bioscience also retains certain limited rights to establish INVO clinics that exclusively commercialize INVO cycles and will retain commercialization rights outside the U.S.
  • "We are pleased to have reached this agreement with Ferring to commercialize INVOcell in the U.S.," said Katie Karloff, Chief Executive Officer of INVO Bioscience.
  • "Ferring has commercial strength and market presence within the pharmaceutical fertility market and understands the unique opportunity that INVOcell provides to revolutionize fertility treatment.
  • "With this agreement, Ferring aims to make INVOcell, a novel technology used in the treatment of infertility, widely available as an option for women and their healthcare providers."

Shady Grove Fertility Atlanta Opens New Full-Service Location in Marietta, Georgia and Welcomes Physician Natalie Stentz, M.D., M.S.C.E. to the Practice

Retrieved on: 
Tuesday, November 6, 2018
Fertility medicine, Human reproduction, Medicine, Health, Infertility, Mycoplasma, Women's health, Reproductive endocrinology and infertility

The expansion in Atlanta is in response to the need for more convenient, highly specialized fertility care in the region.

Key Points: 
  • The expansion in Atlanta is in response to the need for more convenient, highly specialized fertility care in the region.
  • SGF's newest reproductive endocrinologist, Dr. Natalie Stentz joins the award-winning SGF Atlanta team, recognized as Top Doctors for Infertility by Atlanta MagazineDrs.
  • Mark Perloe, Anne Namnoum, and Desire McCarthy-Keithand will be seeing new patients at the Marietta, GA location and Atlanta-Northside location.
  • For more information about SGF Atlanta or to schedule an appointment with an SGF Atlanta physician, call 404-843-2229 or fill out this brief form.

Infertility Treatment Market Worth $2.2 Billion by 2023 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Tuesday, November 6, 2018
Fertility medicine, Sexual reproduction, Human reproduction, Medicine, Infertility, Assisted reproductive technology, Artificial insemination, Reproductive technology, Insemination, Folliculometry

On the basis of product, the Infertility Treatment Market is segmented into equipment, media & consumables, and accessories.

Key Points: 
  • On the basis of product, the Infertility Treatment Market is segmented into equipment, media & consumables, and accessories.
  • The equipment segment is expected to command the largest share of the global Infertility Treatment Market in 2018.
  • Based on procedure, the global Infertility Treatment Market is classified into assisted reproductive technology (ART), artificial insemination (AI), fertility surgery, and other infertility treatment procedures.
  • Asia Pacific is expected to account for the largest share of the global Infertility Treatment Market during the forecast period (2018-2023).

Breakthrough Fertility Procedure Offers New Hope for Infertile Men

Retrieved on: 
Thursday, November 1, 2018
Fertility medicine, Human reproduction, Medicine, Fertility, FNA Mapping, In vitro fertilisation, Assisted reproductive technology, Semen analysis, Infertility, Sperm donation, Paul J. Turek

Men previously thought to be sterile can become biological fathers even after conventional infertility treatments have failed, by undergoing Sperm Mapping , the study shows.

Key Points: 
  • Men previously thought to be sterile can become biological fathers even after conventional infertility treatments have failed, by undergoing Sperm Mapping , the study shows.
  • The research compared two different approaches to surgical sperm retrieval in sterile men to achieve the findings.
  • Using Sperm Mapping, as GPS, sperm were found in all men who had sperm retrieval for IVF-ICSI.
  • This data provides new hope for men hoping to become biological fathers, in the wake of other studies that reportedly found sperm counts falling worldwide.

INVOcell Enables Same-Sex Couple to Both Physically Participate in the Pregnancy and Birth of Their Child

Retrieved on: 
Wednesday, October 31, 2018
Fertility medicine, Human reproduction, Sexual reproduction, Fertility, Medicine, Women's health, Bioethics, Infertility, Pregnancy, Assisted reproductive technology, Reproductive technology

Katie Karloff, Chief Executive Officer of INVO Bioscience, said, "We are thrilled that our INVOcell technology was instrumental in achieving a safe and successful pregnancy.

Key Points: 
  • Katie Karloff, Chief Executive Officer of INVO Bioscience, said, "We are thrilled that our INVOcell technology was instrumental in achieving a safe and successful pregnancy.
  • Enabling both partners to physically participate in the pregnancy is a wonderful benefit of INVOcell.
  • Kathy and Kevin have been great advocates for the efficacy of INVOcell and we greatly appreciate their confidence in our technology."
  • Our lead product, the INVOcell, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology (ART).

Alabama Fertility Welcomes the First INVOcell Baby In the State of Alabama

Retrieved on: 
Tuesday, October 30, 2018
Human reproduction, Fertility medicine, Medicine, RTT, Fertility, Health, Infertility, Mycoplasma, Women's health, Uterine fibroid, Endometriosis, Reproductive endocrinology and infertility

The simplistic INVOcell procedure can be easily performed in an appropriately trained infertility specialist's office without the need for expensive overhead.

Key Points: 
  • The simplistic INVOcell procedure can be easily performed in an appropriately trained infertility specialist's office without the need for expensive overhead.
  • Beth Malizia, MD, a specialist in infertility and reproductive surgery at Alabama Fertility and the first physician trained in the state of Alabama in the INVOcell technique, said, "We are thrilled to announce the birth of the state of Alabama's first INVOcell baby.
  • Alabama Fertility is dedicated to providing a broad scope of services and solutions to help those that desire to achieve pregnancy.
  • Alabama Fertility is an international referral center for complex reproductive problems including endometriosis, uterine fibroids, congenital abnormalities and infertility.

Global Female Infertility Market and Competitive Overview 2014-2023

Retrieved on: 
Friday, October 26, 2018
Fertility, Fertility medicine, Health, Human reproduction, Infertility, Female infertility, Clinical trial

The "Global Female Infertility Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Female Infertility Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering.
  • Global Female Infertility Market and Competitive Landscape - 2018, provides comprehensive insights into Female Infertility pipeline, epidemiology, market valuations, product sales, market forecast, product forecasts, and market shares.
  • The research is classified into following sections - Female Infertility overview with definitions, symptoms, etiology, diagnosis, treatment options; Female Infertility pipeline insights covering late stage clinical trials pipeline; Female Infertility prevalence trends by countries; Female Infertility market size and forecast by countries, market events, trends; product sales and forecast by countries; market shares by countries.
  • Female Infertility pipeline: Find out the drugs in clinical trials for Female Infertility by stages, phase 3 clinical trials, phase 2 clinical trials, and phase 1 clinical trials, by pharmacological class, by company
    Female Infertility epidemiology: Find out the prevalence of Female Infertility by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan; prevalence forecast to 2023
    Female Infertility products: Identify key products marketed and prescribed for Female Infertility by brand name, by molecule, by company, by branded / generic, by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan
    Female Infertility market size: Find out the market size for Female Infertility drugs by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan; Find out how the market advanced from 2014
    Female Infertility drug sales: Find out the sales of Female Infertility drugs by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan, Global
    Female Infertility drugs sales forecast: Sales forecast for Female Infertility drugs to 2023 by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan
    Female Infertility market share analysis: Find out the market shares of Female Infertility drugs and outlook by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan
    Did you know that we also offer Custom Research?

The global human chorionic gonadotropin (hCG) market generated a revenue of $688 million in 2017 and is expected to reach $1,239 million by 2025, registering a CAGR of 7.6% from 2018 to 2025

Retrieved on: 
Tuesday, October 23, 2018
Endocrine system, Anatomy, Human reproduction, Scrotum, Testicle, Fertility medicine, Fertility, Male genital disorders, Cryptorchidism, Hypogonadism, Infertility, Male infertility

It is widely being used to treat infertility-related problems in women as well as increase sperm count in men.

Key Points: 
  • It is widely being used to treat infertility-related problems in women as well as increase sperm count in men.
  • Moreover, it is used to treat cryptorchidism in young boys, a condition when the testicles have not dropped down into the scrotum normally.
  • Significant surge in infertility issues among men & women and increase in prevalence of hypogonadism in geriatric population drive the growth of the global hCG market.
  • A quantitative analysis from 2017 to 2025 is discussed to enable the stakeholders to capitalize on the prevailing market opportunities.

In-vitro Fertilization Market to Gain Strength From Rising Awareness About Male Infertility and Medical Tourism in Developing Economies, Says TMR

Retrieved on: 
Monday, October 22, 2018
Human reproduction, Fertility medicine, Fertility, Sexual reproduction, Infertility, Mycoplasma, Women's health, In vitro fertilisation

The global in-vitro fertilization market is primarily driven by the rising worldwide demand for assistive reproductive technologies.

Key Points: 
  • The global in-vitro fertilization market is primarily driven by the rising worldwide demand for assistive reproductive technologies.
  • The rising awareness about the growing problem of male infertility, especially in developed nations, is also boosting the in-vitro fertilization market.
  • The rapid advances in medical tourism in developing economies is supporting the rapid expansion of the in-vitro fertilization market.
  • Substantial efforts in developing better performing reagents are expected to bolster the demand for reagents in the in-vitro fertilization market.

Rutledge Cancer Foundation Honors Dr. Anna Nackley of CARE Fertility with the "Heart of Gold" Award for Fertility Preservation Services for Cancer Patients

Retrieved on: 
Monday, October 8, 2018
Fertility medicine, Medicine, Human reproduction, Fertility, Fertility preservation, Infertility, Radiation therapy, Assisted reproductive technology, Oncofertility

DALLAS, Oct. 08, 2018 /PRNewswire-PRWeb/ -- The Center for Assisted Reproduction, CARE Fertility , today announces the center was recognized by Rutledge Cancer Foundation with the "Heart of Gold" Award for providing fertility preservation services to young adult patients undergoing cancer treatment.

Key Points: 
  • DALLAS, Oct. 08, 2018 /PRNewswire-PRWeb/ -- The Center for Assisted Reproduction, CARE Fertility , today announces the center was recognized by Rutledge Cancer Foundation with the "Heart of Gold" Award for providing fertility preservation services to young adult patients undergoing cancer treatment.
  • The Rutledge Cancer Foundation hosts the Hearts of Gold Luncheon with a goal of raising awareness and support to care for adolescent and young adult cancer patients.
  • CARE Fertility offers newly-diagnosed cancer patients rapid consultation regarding treatment options for fertility preservation prior to undergoing surgery, radiation or chemotherapy, which can result in future infertility.
  • Fertility preservation options, such as egg and embryo freezing are available at special rates for patients undergoing cancer treatment.